they have already been allocated via a placement to Sophs and Instos, given the amount exceeds the allowable placement capacity in a 12 month period it needs approval by SH’s.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%
